PharmaShots | Incisive News in 3 Shots

Subscribe Now

episodic migraine

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label Treatment Period of P-II Study for Episodic Migraine

October 5, 2020

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

July 12, 2019

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

May 7, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us